Table 1 Baseline demographic and clinical characteristics of the study participants
From: Risk of cancer history in cardiovascular disease among individuals with hypertension
Total | Cancer History (−) | Cancer History (+) | P Value | |
|---|---|---|---|---|
n = 747,620 | n = 721,089 | n = 26,531 | ||
Age, years | 52 (46–59) | 52 (45–59) | 59 (52–64) | <0.001 |
Men, n (%) | 524,722 (70.2) | 509,511 (70.7) | 15,211 (57.3) | <0.001 |
Body Mass Index, kg/m2 | 24.6 (22.2–27.5) | 24.6 (22.2–27.6) | 23.9 (21.5–26.5) | <0.001 |
Obesity, n (%) | 348,056 (46.6) | 337,800 (46.8) | 10,256 (38.7) | <0.001 |
Diabetes Mellitus, n (%) | 92,619 (12.4) | 88,607 (12.3) | 4,012 (15.1) | <0.001 |
Dyslipidemia, n (%) | 449,768 (60.2) | 433,948 (60.2) | 15,820 (59.6) | 0.072 |
Cigarette Smoking, n (%) | 204,125 (27.3) | 200,033 (27.7) | 4,092 (15.4) | <0.001 |
Alcohol Consumption, n (%) | 255,504 (34.2) | 247,198 (34.3) | 8,306 (31.3) | <0.001 |
Physical Inactivity, n (%) | 402,973 (53.9) | 389,121 (54.0) | 13,852 (52.2) | <0.001 |
Systolic Blood Pressure, mmHg | 140 (129–148) | 140 (129–148) | 138 (126–147) | <0.001 |
Diastolic Blood Pressure, mmHg | 89 (80–95) | 89 (80–95) | 85 (77–92) | <0.001 |
Antihypertensive medications, n (%) | 337,164 (45.1) | 321,020 (44.5) | 16,144 (60.8) | <0.001 |
Glucose, mg/dL | 98 (90–107) | 97 (90–107) | 99 (91–109) | <0.001 |
Low-Density Lipoprotein Cholesterol, mg/dL | 125 (105–147) | 125 (105–147) | 122 (101–143) | <0.001 |
High-Density Lipoprotein Cholesterol, mg/dL | 58 (49–71) | 58 (49–71) | 62 (51–75) | <0.001 |
Triglycerides, mg/dL | 107 (74–159) | 107 (74–159) | 102 (72–148) | <0.001 |
